Methods of using Bcl-2 for the therapeutic treatment and...

Chemistry: molecular biology and microbiology – Micro-organism – tissue cell culture or enzyme using process... – Using tissue cell culture to make a protein or polypeptide

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C435S326000, C435S334000, C435S455000, C435S069600, C800S018000

Reexamination Certificate

active

07427495

ABSTRACT:
The invention provides a method of treating a disease or pathological condition resulting in apoptotic cell death. The method includes increasing the activity of Bcl-2 in cells affected by the disease or pathological condition. Diseases or pathological conditions can include, for example, neurodegenerative diseases, cancer and viral infections. Also provided is a method of prolonging the in vivo survival of transplanted cells for the treatment of a disease or pathological condition. The method includes increasing the activity of Bcl-2 in a population of cells and transplanting the population of cells having increased Bcl-2 activity into a subject. Diseases or pathological conditions can include, for example, neurodegenerative diseases, cancer and viral infections. A method to enhance the sensitivity of malignant cells to therapy is provided that includes decreasing the activity of Bcl-2 in the malignant cells. Methods to identify compounds that alter apoptotic cell death and to enhance monoclonal antibody production are also provided by the invention disclosed herein.

REFERENCES:
patent: 4271145 (1981-06-01), Wands et al.
patent: 4997764 (1991-03-01), Favera
patent: 5024947 (1991-06-01), Inlow et al.
patent: 5149628 (1992-09-01), Croce
patent: 5202429 (1993-04-01), Tsujimoto et al.
patent: 5328844 (1994-07-01), Moore
patent: WO 92/22640 (1992-12-01), None
patent: WO 93/20200 (1993-10-01), None
Deonarain et al. (1998) Exp. Opin. Ther. Pat., vol. 8 (1), 53-69.
Miller et al. (1995) FASEB, vol. 9, 190-199.
Stites et al. (1982) Basic & Clinical Immunology, 4th Ed., Chapter 22, pp. 362-363.
Nunez et al. (1989) PNAS, vol. 86, 4589-4593.
Strasser et al. (1991) PNAS, vol. 88, 8661-8665.
Pettersson et al. (1992) Blood, vol. 79 (2), 495-502.
Anton et al., “Use of the anti-apoptotic geneBCL-2in neural transplantation,”Society for Neuroscience Abstracts19:1053 (1993).
Behl et al., “BCL-2 prevents killing of neuronal cells by glutamate but not by amyloid β protein,”Biochem.&Biophys. Res. Comm. 197:949-956 (1993).
Cheung et al., “The tyrosine kinase LCK is critically involved in the growth transformation of human B lymphocytes,”J. Biol. Chem. 266:8667-8670 (1991).
Cleary et al., “Cloning and structural analysis of cDNAs for Bcl-2 and a hybrid Bcl-2 /immunoglobulin transcript resulting from the t(14;18) translocation,”Cell47:19-28 (1986).
Clem et al., “Prevention of apoptosis by a Baculovirus gene during infection of insect cells,”Science324:1388-1390 (1991).
Coghlan, “Gene dream fades away,”New Sci. 148:14-15 (1995).
Donahue et al., “Helper virus induced T cell lymphoma in nonhuman primates after retroviral mediated gene transfer,”J. Exp. Med. 176:1125-1135 (1992).
Dunphy et al., “Mitosis-inducing factors are present in a latent form during interphase in the Xenopus embryo,”J. Cell. Biol. 106:2047-2056 (1988).
Franceschi, “Cell proliferation, cell death and aging,”Aging, 1:3-15 (1989).
Garcia et al., “Prevention of programmed cell death of sympathetic neurons by the Bcl-2 proto-oncogene,”Science258:302-304 (1992).
Goodrich et al., “Abrogation by c-myc on G1 phase arrest induced by RB protein but not by p53,”Nature360:177-179 (1992).
Grogg et al., “CD4+ T cell-mediated killing of major histocompatibility complex class II-positive antigen-presenting cells (APC) III,”Eur. J. Immunol. 22:267-272 (1992).
Harlow and Lane,Antibodies: A Laboratory Manual(Cold Spring Harbor Laboratory, 1988), p. 203 and 277-280.
Henderson et al., “Induction of Bcl-2 expression by Epstein-Barr virus latent membrane protein 1 protects infected B cells from programmed cell death,”Cell65:1107-1115 (1991).
Hockenberry et al., “Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death,”Nature348:334-336 (1990).
Huang et al., “Suppression of the neoplastic phenotype by replacement of the RB gene in human cancer cells,”Science242:1563-1566 (1988).
Itoh et al., “Overexpression of bcl-2, apoptosis suppressing gene: Prolonged viable culture period of hybridoma and enhanced antibody production,”Biotechnology and Bioengineering48:118-122 (1995).
Karson et al., “Prospects for human gene therapy,”J. Rep. Med. 37:508-514 (1992).
Katsumata et al., “Differential effects of Bcl-2 on T and B cells in transgenic mice,”Proc. Natl. Acad. Sci. USA89:11376-11380 (1992).
Ledley, “Clinical considerations in the design of protocols for somatic gene therapy,”Human Gene Therapy2:77-83 (1991).
Levine et al., “Conversion of lytic to persistent alphavirus infection by the Bcl-2 cellular oncogene,”Nature361:739-742 (1993).
Marshall, “Gene therapy's growing pains,”Science269:1050,1052-1055 (1995).
McDonnell and Korsmeyer, “Progression from lymphoid hyperplasia to high-grade malignant lymphoma in mice transgenic for the t(14;18),”Nature349:254-256 (1991).
Miyashita et al., “Bcl-2 gene transfer increases relative resistance of s49.1 and WEHI7.2 lymphoid cells to cell death and DNA fragmentation induced by glucocorticoids and multiple chemotherapeutic drugs,”Cancer Res. 52:5407-5411 (1992).
Miyashita et al., “Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line,”Blood81:151-157 (1993).
Newmeyer et al., “Egg extracts for nuclear import and nuclear assembly reactions,”Methods in Cell Biology36:607-634 (1991).
Orkin, “Hematopoiesis: how does it happen?”Curr. Opin. Cell. Biol. 7:870-877 (1995).
Perlmutter et al., “Structure and expression of LCK transcripts in human lymphoid cells,”J. Cell. Biochem. 38:117-126 (1988).
Potter, “Neoplastic development in B-lymphocytes,”Carcinogenesis11:1-13 (1990).
Raff, “Social controls on cell survival and cell death,”Nature356:397-400 (1992).
Reed et al., “Antisense-mediated inhibition of BCL2 protooncogene expression and leukemic cell growth and survival: Comparisons of phosphodiester and phosphorothioate oligodeoxynucleotides,”Cancer Res. 50:6565-6570 (1990).
Schwartzman et al., “Internucleosomal deoxyribonucleic acid cleavage activity in apoptotic thymocytes: Detection and endocrine regulation,”Endocrinology128:1190-1197 (1991).
Sentman et al., “Bcl-2 inhibits multiple forms of apoptosis but not negative selection in thymocytes,”Cell67:879-888 (1991).
Sinkovics et al., “Apoptosis by genetic engineering,”Leukemia8:98-102 (1994).
Strasser et al., “Bcl-2 transgene inhibits T cell death and perturbs thymic self-censorship,”Cell67:889-899 (1991).
Vaux et al., “Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells,”Nature335:440-442 (1988).
Vaux, “Toward an understanding of the molecular mechanisms of physiological cell death,”Proc. Natl. Acad. Sci. USA90:786-789 (1993).
Williams, “Programmed cell death: Apoptosis and oncogenesis,”Cell65:1097-1098 (1991).
Yang, “Gene transfer into mammalian somatic cells in vivo,”Critical Rev. in Biotech. 12:335-356 (1992).
Yunis et al., “Bcl-2 and other genomic alterations in the prognosis of large-cell lymphoma,”New England Journal of Medicine320:1047-1054 (1989).
Ebert et al., “A Moloney MLV-rat somatotropin fusion gene produces biologically active somatotropin in a transgenic pig,”Mol. Endocrinol., 2(3):277-283 (1988).
Hammer et al., “Genetic engineering of mammalian embryos,”J. Anim. Sci., 63(1):269-278 (1986).
Kappel et al., “Regulating gene expression in transgenic animals,”Curr. Opin. Biotechnol., 3(5):548-553 (1992).
Strojek et al., “The use of transgenic animal techniques for livestock improvement,”Genetic Engineering: Principles and Methods, 10:221-246 (1988).
Tsujimoto et

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Methods of using Bcl-2 for the therapeutic treatment and... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods of using Bcl-2 for the therapeutic treatment and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of using Bcl-2 for the therapeutic treatment and... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-3967972

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.